INTERNATIONAL AIDS VACCINE INITIATIVE INC.
Federal contractor profile
Total Awards
3
Total $
$194.8M
Top Agency
Department of Health and Human Services
NAICS Count
1
Total Awards
3
Total Obligated
$194.8M
Agencies Served
1
Expiring Contracts
3
Top Agencies
| Agency | Awards | Total Obligated |
|---|---|---|
| Department of Health and Human Services | 3 | $194.8M |
Top NAICS Codes
| NAICS Code | Description | Awards |
|---|---|---|
| 541714 | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) | 3 |
Expiring Contracts (3)
75A50121C00077539 days remaining
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN
Department of Health and Human Services|Expires Nov 30, 2027
$95.6M
75A50121C00077539 days remaining
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN
Department of Health and Human Services|Expires Nov 30, 2027
$95.6M
75N93023F00001205 days remaining
CONTRACT HHSN272201800010I INTERNATIONAL AIDS VACCINE INITIATIVE MANUFACTURE OF INFLUENZA VIRUS HUMAN CHALLENGE MATERIAL FOR PHASE I AND II CLINICAL TESTING
Department of Health and Human Services|Expires Dec 31, 2026
$3.6M
All Awards
FIRM FIXED PRICENO SET ASIDE USED.
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN
Department of Health and Human Services75A50121C00077$95.6M
FIRM FIXED PRICENO SET ASIDE USED.
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN
Department of Health and Human Services75A50121C00077$95.6M
COST PLUS FIXED FEE
CONTRACT HHSN272201800010I INTERNATIONAL AIDS VACCINE INITIATIVE MANUFACTURE OF INFLUENZA VIRUS HUMAN CHALLENGE MATERIAL FOR PHASE I AND II CLINICAL TESTING
Department of Health and Human Services75N93023F00001$3.6M